1/10/2011

The FDA pushed back an approval decision on vandetanib, a drug for medullary thyroid cancer, after maker AstraZeneca submitted a plan for risk evaluation and mitigation. The agency is scheduled to complete its review by April 7.

Full Story:
Google

Related Summaries